Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Date publication

juillet 2017

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28525370

Résumé

Using mathematical modelling allows to select a treatment's regimen across infinite possibilities. Here, we report the phase I assessment of a new schedule for metronomic vinorelbine in treating refractory advanced NSCLC and mesothelioma patients.

Mots clés

lung cancer, mathematical modeling, mesothelioma, metronomic, vinorelbine

Référence

Oncotarget. 2017 Jul 18;8(29):47161-47166